Cargando…

A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia

BACKGROUND: Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetaxel-cyclophosphamide (TC) chemotherapy for early-stage breast cancer (EBC). A pragmatic randomised trial compared the superiority of G-CSF to ciprof...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clemons, Mark, Fergusson, Dean, Joy, Anil A., Thavorn, Kednapa, Meza-Junco, Judith, Hiller, Julie Price, Mackey, John, Ng, Terry, Zhu, Xiaofu, Ibrahim, Mohammed F.K., Sienkiewicz, Marta, Saunders, Deanna, Vandermeer, Lisa, Pond, Gregory, Basulaiman, Bassam, Awan, Arif, Pitre, Lacey, Nixon, Nancy A., Hutton, Brian, Hilton, John F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095051/ https://www.ncbi.nlm.nih.gov/pubmed/33901921 http://dx.doi.org/10.1016/j.breast.2021.03.012

Ejemplares similares

Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial
por: Awan, Arif, et al.
Publicado: (2021)

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review
por: Fernandes, Ricardo, et al.
Publicado: (2017)

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial)
por: Hilton, John, et al.
Publicado: (2018)

Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
por: AlZahrani, Mashari, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
por: Tu, Megan M., et al.
Publicado: (2021)

A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer
por: Dent, Susan, et al.
Publicado: (2021)

Timing of recombinant human granulocyte colony-stimulating factor administration on neutropenia induced by cyclophosphamide in normal mice.
por: Misaki, M., et al.
Publicado: (1998)

A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting
por: Clemons, M., et al.
Publicado: (2020)

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

Granulocyte Antibodies in Korean Neonates with Neutropenia
por: Han, Tae Hee, et al.
Publicado: (2006)

Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation
por: McGee, Sharon, et al.
Publicado: (2021)

Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey
por: McGee, Sharon, et al.
Publicado: (2021)

Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer
por: Awan, Arif, et al.
Publicado: (2020)

Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
por: Alzahrani, Mashari, et al.
Publicado: (2021)

Can routinely collected administrative data effectively be used to evaluate and validate endpoints used in breast cancer clinical trials? Protocol for a scoping review of the literature
por: Shah, Hely, et al.
Publicado: (2023)

Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
por: Choi, Jae Hee, et al.
Publicado: (2021)

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
por: Hilton, J.F., et al.
Publicado: (2017)

Strategies for obtaining bone biopsy specimens from breast cancer patients – Past experience and future directions
por: Ibrahim, Mohammed F.K., et al.
Publicado: (2016)

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors
por: Kelly, S, et al.
Publicado: (2009)

A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction
por: Arnaout, Angel, et al.
Publicado: (2020)

Prospective randomised controlled trial using the REthinking Clinical Trials (REaCT) platform and National Surgical Quality Improvement Program (NSQIP) to compare no preparation versus preoperative oral antibiotics alone for surgical site infection rates in elective colon surgery: a protocol
por: Apte, Sameer S, et al.
Publicado: (2020)

Protocol for a modelling study to assess the clinical and cost-effectiveness of indefinite anticoagulant therapy for first unprovoked venous thromboembolism
por: Khan, Faizan, et al.
Publicado: (2023)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Dose-Dependent Effect of Granulocyte Transfusions in Hematological Patients with Febrile Neutropenia
por: Teofili, Luciana, et al.
Publicado: (2016)

Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
por: Wojtukiewicz, Marek, et al.
Publicado: (2014)

Functional characteristics of circulating granulocytes in severe congenital neutropenia caused by ELANE mutations
por: Liu, Qiao, et al.
Publicado: (2019)

Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor
por: Dale, David C., et al.
Publicado: (2022)

Optimal frequency of scans for patients on cancer therapies: A population kinetics assessment
por: Stewart, David J., et al.
Publicado: (2019)

Integrating Systematic Reviews into Supportive Care Trial Design: The Rethinking Clinical Trials (REaCT) Program
por: Alshamsan, Bader, et al.
Publicado: (2022)

Regularly scheduled physical examinations and the detection of breast cancer recurrences
por: Beltran-Bless, Ana-Alicia, et al.
Publicado: (2023)

Granulocyte Colony-stimulating Factor for Preterms with Sepsis and Neutropenia: A Randomized Controlled Trial
por: Chaudhuri, Jasodhara, et al.
Publicado: (2012)

Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers
por: Cole, Katherine Marie, et al.
Publicado: (2021)

Benefits and obstacles to cell therapy in neonates: The INCuBAToR (Innovative Neonatal Cellular Therapy for Bronchopulmonary Dysplasia: Accelerating Translation of Research)
por: Thébaud, Bernard, et al.
Publicado: (2021)

Stimulation of granulocytic colony formation in agar diffusion chambers implanted in cyclophosphamide pretreated mice.
por: Gordon, M. Y., et al.
Publicado: (1975)

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
por: Aapro, Matti, et al.
Publicado: (2010)

Congenital Neutropenia with Specific Granulocyte Deficiency Caused by Novel Double Heterozygous SMARCD2 Mutations
por: Ibrahim, Abukhiran, et al.
Publicado: (2022)

Granulocyte-colony-stimulating Factor-resistant Neutropenia and Polyneuropathy Presenting as Severe Complications of Sjögren's Syndrome
por: Tomita, Katsuyuki, et al.
Publicado: (2022)

Cyclophosphamide/doxorubicin/prednisone: Prolonged COVID-19 viral shedding, neutropenia and thrombocytopenia: case report
Publicado: (2021)

The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design
por: Saunders, Deanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_497n1uv5euqm2io78acmj9ftj4